Skip to content
Screener

Gyre Therapeutics, Inc. GYRE Cash Flow Statement

Q3 '26Q2 '26Q1 '26Q4 '25Q3 '25
-$2.48M-129%-$22.99M—-$9.86M-364%——$8.54M+199%
$467K+66.2%$1.48M+47.0%$672K+25.6%$656K+42.3%$281K-36.9%
$1.73M+181%$2.08M+44.5%$2.58M+409%$4.6M+711%$617K+160%
-$3.98M-128%-$16.73M-124%$3.18M+2,565%——$14.24M—
$979K+66.2%$262K-21.8%$178K+45.9%$144K—$589K-15.0%
$1.73M+131%$9.76M+621%-$3.06M-255%——-$5.64M-136%
$221K-91.1%——$21K-98.4%$318K-67.0%$2.47M+663%
-$1.64M-115%-$6.34M-145%$431K-86.7%——$11.27M+4,980%
-$4.96M-136%-$16.99M-118%$3M+1,296%-$5.77M-114%$13.65M—

FAQ

What is Gyre Therapeutics, Inc.'s free cash flow?
After $1.6M of capital expenditures, Gyre Therapeutics, Inc.'s free cash flow was -$24.7M over the trailing twelve months, down 953.5% year over year.
Where does Gyre Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.